AllTrials: will it catch on in the US?
This article was originally published in SRA
News that the AllTrials campaign has been launched in the US will be welcomed by transparency advocates. But it will be viewed with great disquiet by those in the pharmaceutical industry and elsewhere who are open to a degree of greater clinical trial disclosure but draw the line at releasing patient-level data.
You may also be interested in...
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.